Royalty Pharma Declares Second Quarter 2023 Dividend

Rhea-AI Summary

The board of directors of Royalty Pharma (Nasdaq: RPRX) has declared a dividend of $0.20 per Class A ordinary share for the second quarter of 2023. This dividend will be distributed on June 15, 2023, to shareholders recorded by the close of business on May 19, 2023. Founded in 1996, Royalty Pharma is the largest purchaser of biopharmaceutical royalties, collaborating across the industry to fund innovation. Its portfolio includes royalties from over 35 commercial products like Vertex’s Trikafta and AbbVie’s Imbruvica, among others. The company plays a pivotal role in funding both late-stage clinical trials and acquiring existing royalties, supporting advancements in biopharmaceuticals.

Positive

• Approval of a dividend of $0.20 per share enhances shareholder returns.
• The dividend reflects the company's strong financial position and commitment to returning value to shareholders.
• A portfolio of royalties from over 35 commercial products provides a diverse income stream.

Negative

• None.

NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2023 of $0.20 per Class A ordinary share.

The dividend will be paid on June 15, 2023, to shareholders of record at the close of business on May 19, 2023.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 11 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

What is the dividend amount for Royalty Pharma in Q2 2023?

The dividend amount is $0.20 per Class A ordinary share.

When will the dividend for Royalty Pharma be paid?

The dividend will be paid on June 15, 2023.

What is the record date for Royalty Pharma's Q2 2023 dividend?

The record date is May 19, 2023.

What types of products does Royalty Pharma have royalties on?

Royalty Pharma has royalties on over 35 commercial products, including therapies from Vertex, Biogen, and AbbVie.

How does Royalty Pharma fund innovation in biopharmaceuticals?

Royalty Pharma funds innovation by co-funding late-stage clinical trials and acquiring existing royalties from innovators.